Vanda Pharmaceuticals Inc. logo

Vanda Pharmaceuticals Inc. (VNDA)

Market Closed
14 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
4. 97
+0.23
+4.85%
Pre Market
$
4. 84
-0.13 -2.62%
288.19M Market Cap
18.48 P/E Ratio
0% Div Yield
951,200 Volume
-0.01 Eps
$ 4.74
Previous Close
Day Range
4.67 5.04
Year Range
3.81 6.37
Want to track VNDA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 14 days
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.07 per share a year ago.

Zacks | 2 months ago
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Andrew Tsai - Jefferies Operator Hello, and thank you for standing by.

Seekingalpha | 5 months ago
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.

Zacks | 5 months ago
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.

Zacks | 6 months ago
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Vanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt and PONVORY distribution. I'm interested in buying the stock prior to FY 2024 results being announced in February.

Seekingalpha | 6 months ago
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Seekingalpha | 8 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Accesswire | 8 months ago
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. VNDA, a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.

Benzinga | 8 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Accesswire | 8 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Accesswire | 8 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Accesswire | 8 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Accesswire | 8 months ago
Loading...
Load More